Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06814067
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase II Multicentered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Sponsor: Fudan University
Interventions
Adjuvant radiotherapy Ivonescimab Pembrolizumab Surgery
Updated 1 time since 2025 Last updated: Feb 3, 2025 Started: Feb 10, 2025 Primary completion: Feb 10, 2029 Completion: Mar 1, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06814067, this PHASE2 trial focuses on Head and Neck Squamous Cell Carcinoma and Head and Neck Squamous Cell Carcinoma HNSCC and remains actively recruiting participants. Sponsored by Fudan University, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fudan University
- Fujian Cancer Hospital
Data source: Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .